Berns Paul L

See Remarks, DirectorNeumora Therapeutics, Inc. (NMRA) · full profile →Form 4 · filed May 30, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
8
0 non-derivative · 8 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 28, 2025Disposed to issuer(D)956K0
May 28, 2025Disposed to issuer(D)343K0
May 28, 2025Grant(A)2.0M2.0M
May 28, 2025Grant(A)497K497K
May 28, 2025Grant(A)956K956K
May 28, 2025Grant(A)343K343K
May 28, 2025Disposed to issuer(D)497K0
May 28, 2025Disposed to issuer(D)2.0M0

Transaction Codes

D
Disposition to the issuer
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-079920) within minutes of acceptance. Every field above traces to the original document. Verify it directly: